FDA Drug recall D-1871-2019
Fexofenadine HCL Tablets USP, 180 mg, 500's BRITE STOCK
- FDA Drug
- Class II
- terminated
- Published 2019-09-25
On 2019-09-25 the FDA classified a Class II recall of Fexofenadine HCL Tablets USP, 180 mg, 500's BRITE STOCK by Aurolife Pharma, citing failed Impurities/Degradation Specifications.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1871-2019 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2019-08-23 |
| Published | 2019-09-25 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Aurolife Pharma |
| Distribution | US |
Product
Fexofenadine HCL Tablets USP, 180 mg, 500's BRITE STOCK; Manufactured for: Aurohealth LLC., 2572 Brunswick Pike, Lawrenceville, NJ 08648; Manufactured by: Aurolife Pharma LLC, Dayton, NJ 08810.
Reason
Failed Impurities/Degradation Specifications
Identifiers
| code_info | Lot #s:067180011A, 067180012A, Exp 04/21, 06718027B1, Exp 09/21 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1871-2019%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.